ARTICLE | Product Development

Mapping the path to gene therapy 2.0

Getting to gene therapy 2.0 will require improvements under way, plus an overhaul of manufacturing strategy

January 18, 2020 4:41 AM UTC
Updated on Jan 18, 2020 at 4:33 PM UTC

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to produce the step change necessary for version 2.0.

While gene therapy 1.0 was over 20 years in the making, it left a to-do list centered on repeat dosing and manufacturing as the principal hurdles to becoming broadly used cures for multiple diseases...

BCIQ Company Profiles

Genethon S.A.